News
Sanofi to exercise option on third SAFEbody discovery program and sponsor combination clinical trial with muzastotug - ...
1d
Pharmaceutical Technology on MSNSanofi agrees to invest $25m in AdageneSanofi has agreed to invest up to $25m in Adagene, which will enable the latter to fund its research and development (R&D) ...
2d
InvestorsHub on MSNAdagene Shares Climb on Strengthened Collaboration and $25M Investment from SanofiAdagene Inc. (NASDAQ:ADAG) saw its shares rise by 6.1% on Tuesday after the biotech firm revealed a strategic investment deal ...
Sanofi has doubled down on its partnership with Adagene, investing $25 million in the biotech, taking up its option on a ...
Sanofi agreed to invest up to $25 million in the clinical-stage biotechnology company. Adagene said it plans to use the proceeds to fund its research and development activities, including clinical ...
Sino-American antibody company Adagene (Nasdaq: ADAG) has announced a strategic investment and option exercise by Sanofi ...
Detailed price information for Adagene Inc ADR (ADAG-Q) from The Globe and Mail including charting and trades.
Potential Positives. Sanofi has agreed to a strategic investment of up to US$25 million, which will enhance Adagene's financial stability and extend its cash runway into 2027.
Sanofi has also exercised its option to select a third SAFEbody discovery program, utilizing Adagene’s proprietary masking technology and antibody engineering expertise.
American depositary receipts of Adagene rose 15% in premarket trading following an investment from Sanofi. ADRs were trading around $2.24. The stock is down 2% on the year. Sanofi agreed to invest ...
Sanofi has agreed to make strategic investment of up to US$25 million in Adagene. The Company plans to use the proceeds to fund its research and development activities, including clinical development ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results